RADNOR,
Pa., Jan. 5, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that it will be presenting a scientific update of its
Phase 2 and Phase 3 development program for NRX-101 in the
treatment of suicidal bipolar depression at the upcoming
6th Annual Neuroscience Innovation Forum by Sachs
Associates ("6th Annual NIF"). The forum takes
place Sunday, January 8, 2023, as part of the activities
surrounding the annual J.P. Morgan Healthcare Conference being held
in San Francisco. The forum is
open to registered attendees and a link to the presentation content
is expected to be available on the NRx Pharmaceuticals'
website.
Investors wishing to meet with NRx Pharmaceuticals' executives
during the upcoming JP Morgan Healthcare Conference in San Francisco are invited to contact the
Company's investor relations representatives.
About NRx
Pharmaceuticals
Clinical-stage biopharmaceutical company developing therapeutics
for the treatment of central nervous system disorders, specifically
suicidal depression and post-traumatic stress disorder (PTSD). The
company's lead program NRX-101, an oral, fixed-dose combination of
D-cycloserine and lurasidone, targets the brain's NMDA receptor and
is being investigated in a Phase 3 trial under an FDA Special
Protocol Agreement and Breakthrough Therapy Designation in patients
with bipolar depression and suicidal ideation, an indication for
which the only approved treatment is electroshock therapy. NRx
Pharmaceuticals has also initiated a Phase 2b clinical trial in patients with Sub-Acute
Suicidality, a substantially broader indication. The Breakthrough
Therapy Designation and Special Protocol Agreement were awarded by
the FDA based on the Company's prior STABIL-B trial that
demonstrated substantial improvement over available therapy in
reducing depression and suicidality compared to placebo when
patients were treated with NRX-101 after a single dose of
ketamine.
Cautionary Note Regarding
Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995, which may include, but are not limited to, statements
regarding our financial outlook, product development, business
prospects, and market and industry trends and conditions, as well
as the Company's strategies, plans, objectives, and goals. These
forward-looking statements are based on current beliefs,
expectations, estimates, forecasts, and projections of, as well as
assumptions made by, and information currently available to, the
Company's management.
The Company assumes no obligation to revise any forward-looking
statement, whether as a result of new information, future events or
otherwise. Accordingly, you should not place reliance on any
forward-looking statement, and all forward-looking statements are
herein qualified by reference to the cautionary statements set
forth above.
CORPORATE CONTACT
Molly Cogan
Sr. Director, Global Communications and Government Affairs
mcogan@nrxpharma.com
INVESTOR RELATIONS
Suzanne Messere
Investor Relations
suzanne.messere@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-present-scientific-update-at-the-6th-annual-sachs-associates-neuroscience-innovation-forum-in-conjunction-with-the-2023-jp-morgan-healthcare-conference-301714196.html
SOURCE NRx Pharmaceuticals, Inc.